Adenoid Cystic Carcinoma of Bartholin Gland: Case Report

Adenoid cystic carcinoma (ACC) is a rare and often slow-growing, yet aggressive, malignancy. While it can occur in various parts of the body, it rarely affects the Bartholin’s gland – a small gland located near the vaginal opening. When it does, it presents unique diagnostic and therapeutic challenges. Recent case reports and literature reviews are shedding light on this uncommon condition, helping clinicians better understand its presentation, treatment, and potential for recurrence.

Understanding Adenoid Cystic Carcinoma of the Bartholin’s Gland

ACC of the Bartholin’s gland (ACCBG) accounts for a very small percentage of all vulvar carcinomas, ranging from 0.1% to 7%, and represents 0.001% of all female genital tract malignancies. The rarity of this cancer means that there is no single, universally accepted treatment protocol. Diagnosis often involves recognizing a solid mass in the vulvar region, which may cause symptoms like pain, a feeling of fullness, or discomfort during intercourse.

Diagnostic Challenges and Treatment Approaches

A case report published in March 2022 detailed the case of a 42-year-old woman diagnosed with ACCBG. The patient presented with symptoms including pain during intercourse, a sensation of a foreign body in the vagina, a palpable mass, and vaginal pain. The report highlights the importance of considering ACCBG in the differential diagnosis of vulvar masses, even in the absence of typical symptoms.

Treatment strategies for ACCBG have varied across reported cases. Options include radical vulvectomy (removal of the entire vulva), hemi-vulvectomy (removal of half of the vulva), wide or local excision of the tumor, and other surgical approaches. A review of 100 published cases revealed that radical vulvectomy was performed in 30% of patients, hemi-vulvectomy in 17%, wide excision in 21%, and local excision in 24%.

The Role of Radiation Therapy

Postoperative radiation therapy (RT) is frequently employed, with approximately 44% of patients receiving it. The decision to use RT is often influenced by the presence of positive margins – meaning cancer cells were found at the edge of the tissue removed during surgery – with 71.9% of patients with positive margins receiving RT compared to 29.5% of those with negative margins. However, research suggests that RT may be beneficial even in patients with negative margins, reducing the risk of local relapse. Specifically, the risk of local relapse was 15.4% with RT versus 41.9% without RT in patients with negative margins, and 13% with RT versus 33.3% without RT in patients with positive margins.

While adjuvant RT (RT given after surgery) appears to reduce the risk of local recurrence, a study found that the overall risk of relapse of any type was 40.9% in patients who received RT compared to 48.2% in those who did not. The median time to relapse across all cases was 24 months, with a range of 6 to 156 months.

Genomic Profiling and Targeted Therapies

Advances in genomic profiling are beginning to offer new insights into ACCBG. In one case report, genomic analysis of the tumor revealed a MYB-NFIB fusion transcript and a somatic mutation of PLCG1. This led to the use of lenvatinib, a targeted therapy, in an attempt to control the disease. This highlights the potential for personalized treatment approaches based on the specific genetic characteristics of the tumor.

Metastasis and Prognosis

When ACCBG does metastasize (spread to other parts of the body), the lungs and bones are the most common sites. In the reviewed cases, lung metastasis occurred in 76.7% of patients, and bone metastasis in 26.7%. The slow growth of ACC is often deceptive, as it can recur many years after initial treatment.

Current Limitations and Future Directions

Due to the extreme rarity of ACCBG, establishing optimal treatment strategies remains a challenge. The current understanding is largely based on case reports and retrospective reviews. More research is needed to determine the most effective surgical techniques, the role of adjuvant therapies like RT, and the potential benefits of targeted therapies based on genomic profiling. Pooling data from published case reports is crucial for improving our understanding of this rare disease and guiding therapeutic decisions.

The information presented here is for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.